Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1953 1
1955 3
1956 2
1958 2
1959 1
1960 2
1961 3
1962 1
1963 4
1964 3
1967 1
1968 4
1969 6
1970 4
1971 2
1972 1
1973 1
1975 5
1976 4
1977 2
1978 5
1979 2
1980 7
1981 5
1982 7
1983 7
1984 11
1985 11
1986 9
1987 12
1988 7
1989 9
1990 16
1991 8
1992 11
1993 9
1994 14
1995 7
1996 10
1997 12
1998 20
1999 33
2000 30
2001 44
2002 23
2003 29
2004 31
2005 35
2006 44
2007 32
2008 25
2009 27
2010 36
2011 37
2012 28
2013 30
2014 41
2015 50
2016 47
2017 47
2018 54
2019 54
2020 64
2021 49
2022 45
2023 41
2024 15

Text availability

Article attribute

Article type

Publication date

Search Results

1,141 results

Results by year

Filters applied: . Clear all
Page 1
Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer.
Hotta K, Hida T, Nokihara H, Morise M, Kim YH, Azuma K, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Kumagai T, Watanabe S, Goto K, Satouchi M, Kozuki T, Shukuya T, Nakagawa K, Mitsudomi T, Yamamoto N, Asakawa T, Yoshimoto T, Takata S, Tamura T. Hotta K, et al. Among authors: kumagai t. ESMO Open. 2022 Aug;7(4):100527. doi: 10.1016/j.esmoop.2022.100527. Epub 2022 Jul 14. ESMO Open. 2022. PMID: 35843080 Free PMC article. Clinical Trial.
Tumor-derived semaphorin 4A improves PD-1-blocking antibody efficacy by enhancing CD8+ T cell cytotoxicity and proliferation.
Naito Y, Koyama S, Masuhiro K, Hirai T, Uenami T, Inoue T, Osa A, Machiyama H, Watanabe G, Sax N, Villa J, Kinugasa-Katayama Y, Nojima S, Yaga M, Hosono Y, Okuzaki D, Satoh S, Tsuda T, Nakanishi Y, Suga Y, Morita T, Fukushima K, Nishide M, Shiroyama T, Miyake K, Iwahori K, Hirata H, Nagatomo I, Yano Y, Tamiya M, Kumagai T, Takemoto N, Inohara H, Yamasaki S, Yamashita K, Aoshi T, Akbay EA, Hosen N, Shintani Y, Takamatsu H, Mori M, Takeda Y, Kumanogoh A. Naito Y, et al. Among authors: kumagai t. Sci Adv. 2023 May 19;9(20):eade0718. doi: 10.1126/sciadv.ade0718. Epub 2023 May 19. Sci Adv. 2023. PMID: 37205755 Free PMC article.
Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer.
Nakagawa K, Hida T, Nokihara H, Morise M, Azuma K, Kim YH, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Kumagai T, Hotta K, Watanabe S, Goto K, Satouchi M, Kozuki T, Koyama R, Mitsudomi T, Yamamoto N, Asakawa T, Hayashi M, Hasegawa W, Tamura T. Nakagawa K, et al. Among authors: kumagai t. Lung Cancer. 2020 Jan;139:195-199. doi: 10.1016/j.lungcan.2019.11.025. Epub 2019 Nov 28. Lung Cancer. 2020. PMID: 31812890
Nanoscale coherent phonon spectroscopy.
Liu S, Hammud A, Hamada I, Wolf M, Müller M, Kumagai T. Liu S, et al. Among authors: kumagai t. Sci Adv. 2022 Oct 21;8(42):eabq5682. doi: 10.1126/sciadv.abq5682. Epub 2022 Oct 21. Sci Adv. 2022. PMID: 36269832 Free PMC article.
Endotracheal bronchogenic cyst.
Okuyama T, Akazawa Y, Uchida J, Nishino K, Kumagai T, Imamura F. Okuyama T, et al. Among authors: kumagai t. J Bronchology Interv Pulmonol. 2011 Oct;18(4):340-2. doi: 10.1097/LBR.0b013e3182310d41. J Bronchology Interv Pulmonol. 2011. PMID: 23208629
1,141 results